^
    10ms
    A readily available new method of BRAF mutation detection, appropriate for main malignant melanoma subtypes (WCD 2023)
    The new IntelliPlex™ BRAF Mutation Kit offers an economical, efficient, and reliable testing method for malignant melanoma subtypes, and further evaluation can be made in a more extensive series.
    BRAF (B-raf proto-oncogene) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    BRAF V600E • BRAF mutation • BRAF V600
    |
    therascreen® BRAF V600E RGQ PCR
    3years
    [VIRTUAL] The use of ctDNA for BRAF mutations testing in routine clinical practice in patients with advanced melanoma (EADO-WCM 2021)
    "ctDNA is a feasible source of genetic material for BRAF mutations assessment in patients with advanced melanoma in clinical practice, especially when a tissue sample is not available or in patients with rapidly progressive disease. The median TAT for ctDNA testing is significantly shorter than for tissue samples, while sensitivity and specificity are>80% highlighting the clinical utility of liquid biopsy. Treatment with BRAF/MEKi based on the results of liquid biopsy gives comparable outcomes to those reported in the literature for the general population."
    Clinical
    |
    BRAF (B-raf proto-oncogene) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    BRAF mutation • BRAF V600
    |
    cobas® 4800 BRAF V600 Mutation Test • therascreen® BRAF V600E RGQ PCR • AmoyDx® BRAF V600 Mutations Detection Kit